PACB (Pacific Biosciences of California) Momentum Rank: 7 (As of Sep. 16, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PACB Pacific Biosciences of California Inc PACB
55 GF Score
Price $1.35
GF Value $1.47
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Momentum Rank?

Pacific Biosciences of California PACB -0.74% 55 Momentum Rank is 7 as of Sep. 16, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates PACB with a GF Score™ of 55/100 and a GF Value™ of $1.47 (Fairly Valued). The stock has 7 warning signs investors should review.

Pacific Biosciences of California has the Momentum Rank of 7.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pacific Biosciences of California Momentum Rank Related Terms

PACB vs SI, MASS, SGHT: Momentum Rank Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California Momentum Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Momentum Rank falls into.


PACB
55GF Score
Pacific Biosciences of California Inc PACB
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 7 mean?
Pacific Biosciences of California (PACB) has a Momentum Rank of 7 as of Sep. 16, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Pacific Biosciences of California and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Pacific Biosciences of California's Momentum Rank has ranged from 2.00 to 10.00.
Is Pacific Biosciences of California's Momentum Rank too high?
Pacific Biosciences of California's current Momentum Rank of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Pacific Biosciences of California has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Momentum Rank compare to SI and MASS?
Pacific Biosciences of California's Momentum Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Pacific Biosciences of California's own Momentum Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Devices & Instruments company?
A good Momentum Rank depends on the Medical Devices & Instruments industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Momentum Rank is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.47, compared to a current price of $1.35 — trading 8.5% below its estimated fair value. The current Momentum Rank is 7, which is 75% above median its 10-year median of 4.00. Pacific Biosciences of California's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Momentum Rank is 7 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (PACB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of $1.35 is trading 8.5% below its estimated GF Value™ of $1.47. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for PACB:

  • Momentum Rank: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: $1.47 vs. price of $1.35 (8.5% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Biosciences of California Business Description

Other Exchanges P09:Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
55GF Score

Get the complete analysis for PACB

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.35
Price
$1.47
GF Value